Fwd: The effect of hyperbaric oxygen treatment on squamous cell cancer growth and tumor hypoxia.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: The effect of hyperbaric oxygen treatment on squamous cell cancer growth and tumor hypoxia.
To: mesothelioma77@gmail.com


[1]Ann Plast Surg. 2008 Jan; 60(1): 81-8
Schönmeyr BH, Wong AK, Reid VJ, Gewalli F, Mehrara BJ

Anecdotal studies have reported explosive tumor growth in patients with a history of squamous cell carcinoma after hyperbaric oxygen (HBO) treatment. Conflicting experimental results have followed. In this study, squamous cancer cells were subjected to daily HBO treatment. No difference in cellular proliferation was noted in vitro when comparing HBO and control treated cells (P = 0.534). Similarly, immunostaining for in vivo DNA synthesis failed to demonstrate any significant difference in the number of proliferating cells after treatment with HBO (P = 0.388). No significant difference in tumor volume or mass was found after in vivo implantation (P = 0.471). HBO was found to reduce tumor hypoxia, which trended towards significance when compared with controls (P = 0.057); however, there was no difference in serum VEGF levels or vessel ingrowth. Thus, even though HBO may reduce the levels of hypoxia within squamous cell tumors, it does not appear to enhance short-term growth or promote cellular proliferation or angiogenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18281803
--
 

Fwd: Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy).

 

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy).
To: mesothelioma77@gmail.com


[1]Curr Opin Rheumatol. 2008 Jan; 20(1): 100-5
Naschitz JE, Rosner I

PURPOSE OF REVIEW: To examine recent data about the association between rheumatic disorders and cancer. This article focuses on paraneoplastic rheumatic disorders, which usually precede by a short period of time the diagnosis of malignancy, and on malignant transformation, which occurs late in the course of rheumatic disorders. Evidence of causality between malignancies and rheumatic disorders was reviewed based on statistical indicators (standardized incidence ratios and odds ratios) and by applying Bradford Hill's criteria of causality. RECENT FINDINGS: Firm epidemiological evidence was found attesting that dermatomyositis and polymyostis may present as paraneoplastic syndromes. Several other musculoskeletal disorders may be present akin to paraneoplastic syndrome, based on clinicians' impressions, but with scarce epidemiological evidence supporting a causal determinism. In contrast, robust evidence has accumulated on the role of longstanding rheumatoid arthritis, Sjögren's syndrome and systemic sclerosis as premalignant conditions. Evidence that systemic lupus erythematosus may evolve into lymphoma is equivocal. SUMMARY: The link between malignancies and rheumatic disorders may impact on clinical practice. First, paraneoplastic rheumatic syndromes can provide the clinician with hints for earlier diagnosis of occult cancer. Second, the risk of malignant transformation during the course of rheumatic disorders may motivate the search for strategies aimed at prevention.



___
Source: http://www.hubmed.org/display.cgi?uids=18281865
--